Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial

ConclusionsIn ACLF patients with either no or small esophageal varices and HVPG  ≥ 12 mmHg, carvedilol leads to improved survival and fewer AKI and SBP events up to 28 days.ClinicalTrials.gov identifier numberNCT02583698.
Source: Hepatology International - Category: Infectious Diseases Source Type: research